"Prealbumin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease.
| Descriptor ID |
D011228
|
| MeSH Number(s) |
D12.776.034.841.450 D12.776.124.727.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prealbumin".
Below are MeSH descriptors whose meaning is more specific than "Prealbumin".
This graph shows the total number of publications written about "Prealbumin" by people in this website by year, and whether "Prealbumin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 2 | 1 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 2 | 1 | 3 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prealbumin" by people in Profiles.
-
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 May 01; 11(5):446-454.
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
-
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 Jan 01; 11(1):57-67.
-
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27; 153(4):214-225.
-
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
-
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
-
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
-
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 10 26; 389(17):1553-1565.
-
Elucidation of the mechanism of amyloid A and transthyretin formation using mass spectrometry-based absolute quantification. Virchows Arch. 2024 Nov; 485(5):943-946.
-
Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains. Eur Heart J Cardiovasc Imaging. 2023 05 31; 24(6):829-837.